Is it time for ocrelizumab extended interval dosing in relapsing remitting ms? evidence from an italian multicenter experience during the covid-19 pandemic

HIGHLIGHTS

• who: Aurora Zanghì from the Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy have published the paper: Is It Time for Ocrelizumab Extended Interval Dosing in Relapsing Remitting MS? Evidence from An Italian Multicenter Experience During the COVID-19 Pandemic, in the Journal: (JOURNAL)
• what: The authors aimed to assess confirmed disability progression (CDP). The authors aimed to assess CDP with standardized neurologic examinations that are usually scheduled every six months.
• how: The study was conducted in accordance with the ethical principles of the Declaration of Helsinki. on SID. The . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.